Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Spero Therapeutics, Inc. - Common Stock (NQ:SPRO)

0.7542 +0.0142 (+1.92%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 35,943
Open 0.7400
Bid (Size) 0.7542 (29)
Ask (Size) 0.7828 (58)
Prev. Close 0.7400
Today's Range 0.7400 - 0.7860
52wk Range 0.5052 - 1.720
Shares Outstanding 52,571,813
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Earnings Scheduled For March 27, 2025
Via Benzinga
A Glimpse of Spero Therapeutics's Earnings Potential
Via Benzinga

Performance

YTD
-30.2%
-30.2%
1 Month
-1.4%
-1.4%
3 Month
-17.1%
-17.1%
6 Month
-41.1%
-41.1%
1 Year
-48.7%
-48.7%

More News

Read More
The Analyst Verdict: Spero Therapeutics In The Eyes Of 4 Experts
Via Benzinga
What 4 Analyst Ratings Have To Say About Spero Therapeutics
Via Benzinga
Spero Therapeutics's Earnings Outlook
Via Benzinga
Recap: Spero Therapeutics Q4 Earnings
Via Benzinga
Earnings Scheduled For November 14, 2024
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Alphabet Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket
Via Benzinga
SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024
Via InvestorPlace
3 Micro-Cap Moonshots for Fearless Investors
Via InvestorPlace
Earnings Outlook For Spero Therapeutics
Via Benzinga
Recap: Spero Therapeutics Q3 Earnings
Via Benzinga
Earnings Outlook For Spero Therapeutics
Via Benzinga
SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Via InvestorPlace
Earnings Scheduled For March 13, 2024
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Earnings Scheduled For November 13, 2023
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga

Frequently Asked Questions

Is Spero Therapeutics, Inc. - Common Stock publicly traded?
Yes, Spero Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Spero Therapeutics, Inc. - Common Stock trade on?
Spero Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Spero Therapeutics, Inc. - Common Stock?
The ticker symbol for Spero Therapeutics, Inc. - Common Stock is SPRO on the Nasdaq Stock Market
What is the current price of Spero Therapeutics, Inc. - Common Stock?
The current price of Spero Therapeutics, Inc. - Common Stock is 0.7542
When was Spero Therapeutics, Inc. - Common Stock last traded?
The last trade of Spero Therapeutics, Inc. - Common Stock was at 04/17/25 04:00 PM ET
What is the market capitalization of Spero Therapeutics, Inc. - Common Stock?
The market capitalization of Spero Therapeutics, Inc. - Common Stock is 39.65M
How many shares of Spero Therapeutics, Inc. - Common Stock are outstanding?
Spero Therapeutics, Inc. - Common Stock has 40M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.